PREVIOUS ISSUE NEXT ISSUE
April 2017 Default Cover Image
Do you prescribe MET for stone patients?Urology Times reached out to three urologists (selected randomly) and asked them each the following question: Do you prescribe MET for stone patients?
What’s new in prostate Ca tests: Markers, imagingIn this article, urologists Scott E. Eggener, MD, and Stacy Loeb, MD, MSc, discuss the current applications for prostate cancer biomarkers and MRI, their impact on clinical practice, and future developments.
Immunotherapy for GU Ca: A primer for urologistsThis article discusses the current status and potential future developments in immunotherapy for genitourinary malignancies with insights from urologic oncology specialists Hyung L. Kim, MD, and Daniel P. Petrylak, MD.
Biomarkers for bladder cancer: Current and futureThe role of protein- and cell-based urinary biomarkers for bladder cancer detection and surveillance is controversial, and in 2017 these assays have yet to come into widespread use among urologists. Their uptake is expected to increase, however, considering that the AUA/Society of Urologic Oncology “Guideline on Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer” that was released in 2016 identifies situations for using urinary biomarkers, according to Badrinath R. Konety, MD.
Guidelines update: Bladder, kidney, prostate cancerThis article highlights the key points of two urologic cancer guidelines (which provide evidence-based guidance) and two consensus statements (which provide consensus recommendations by a multidisciplinary panel of experts) that have been published in the past year.
Most men prefer informed decision-making for PCaParticipants in an outreach event for prostate cancer screening preferred education about prostate cancer prior to undergoing screening, and thought the use of an informed decision-making model was beneficial, researchers reported at the Genitourinary Cancers Symposium in Orlando, FL.
ASCO issues guidance on second-line hormonal Tx in CRPCThe American Society of Clinical Oncology’s provisional clinical opinion on the use of second-line hormonal therapy for chemotherapy-naïve men with castration-resistant prostate cancer issued by uncovered some surprising findings and issues.
Guarded approval for new USPSTF PSA gradeThe new draft recommendation on PSA screening from the U.S. Preventive Services Task Force (USPSTF), which improves the previous D rating for all men to a C rating for those ages 55 to 69 years, has been met with guarded approval by three of the key national organizations representing urologists.
MACRA: A practical perspective for urologistsThis article provides a practical explanation of MACRA and the Quality Payment Program and what they mean for practicing urologists.
AUA '17 puts emphasis squarely on 'value'In this article, members of the Urology Times editorial advisory board weigh in on the themes and specific sessions that annual meeting attendees should watch for across a variety of health policy and clinical topics.
How to choose the right investment strategy"Determining what to invest in should be based primarily on the needs, temperament, and available resources of each individual or family," write Jeff Witz, CFP, and David Zemon.
Sleep duration linked to PCa mortality risk in younger menResults of a recent study support a growing body of evidence that factors associated with circadian rhythm disruption might play a role in prostate carcinogenesis.
How to charge for E&M services, procedure on same dateIn this "Coding Q&A," the Painters also answer a question regarding coding for sling and cystocele repair with mesh repair.
PREVIOUS ISSUE NEXT ISSUE